Quinacrine enhances cisplatin-induced cytotoxicity in four cancer cell lines

Chemotherapy

Volumn 56, Issue 2, 2010, Pages 127-134

  Wang, Yixiang ^a   Bi, Qingwei ^c   Dong, Ling ^a   Li, Xiao ^b   Ge, Xiyuan ^a   Zhang, Xiaoxia ^a   Fu, Jia ^a   Wu, Dengcheng ^a   Li, Shenglin ^a  

^a PEKING UNIVERSITY   (China)

^b Beijing Haidian Hospital   (China)

^c Department of Oral Surgery   (China)

Author keywords

Bax; Caspase 3; CIAP 1; Cisplatin; Cytotoxicity; Quinacrine

Indexed keywords

CASPASE 3; CISPLATIN; INHIBITOR OF APOPTOSIS PROTEIN 1; MEPACRINE; PROTEIN BAX; PROTEIN P53;

ANIMAL CELL; APOPTOSIS; ARTICLE; CANCER ADJUVANT THERAPY; CANCER CELL CULTURE; CANCER INHIBITION; CELL ASSAY; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOWN REGULATION; DRUG CYTOTOXICITY; DRUG MECHANISM; HELA CELL; HUMAN; HUMAN CELL; NICK END LABELING; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; UPREGULATION; WESTERN BLOTTING;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; BLOTTING, WESTERN; CELL LINE, TUMOR; CHEMOTHERAPY, ADJUVANT; CISPLATIN; DOSE-RESPONSE RELATIONSHIP, DRUG; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IN SITU NICK-END LABELING; MICE; NEOPLASMS; QUINACRINE; RATS; SINCALIDE;

EID: 77952263996     PISSN: 00093157     EISSN: None     Source Type: Journal    
DOI: 10.1159/000313525     Document Type: Article

References (30)

1. Sarkar FH, Li YW: Targeting multiple signal pathways by chemopreventive agents for cancer prevention and therapy. Acta Pharmacol Sin 2007; 28: 1305-1315.
2. Kitada N, Takara K, Itoh C, Minegaki T, Tsujimoto M, Sakaeda T, Yokoyama T: Comparative analysis of cell injury after exposure to antitumor platinum derivatives in kidney tubular epithelial cells. Chemotherapy 2008; 54: 217-223.
3. Somali I, Alacacioglu A, Tarhan MO, Meydan N, Erten C, Usalp S, Yilmaz U: Cisplatin plus gemcitabine chemotherapy in taxane/ anthracycline-resistant metastatic breast cancer. Chemotherapy 2009; 55: 155-160.
4. Yazici YD, Kim S, Jasser SA, Wang Z, Carter KB, Jr., Bucana CD, Myers JN: Antivascular therapy of oral tongue squamous cell carcinoma with PTK787. Laryngoscope 2005; 115: 2249-2255.
5. Perez RP: Cellular and molecular determinants of cisplatin resistance. Eur J Cancer 1998; 34: 1535-1542.
6. Liang GW, Lu WL, Wu JW, Zhao JH, Hong HY, Long C, Li T, Zhang YT, Zhang H, Wang JC, Zhang X, Zhang Q: Enhanced therapeutic effects on the multi-drug resistant human leukemia cells in vitro and xenograft in mice using the stealthy liposomal vincristine plus quinacrine. Fundam Clin Pharmacol 2008; 22: 429-437.
7. Upcroft P, Upcroft JA: Drug targets and mechanisms of resistance in the anaerobic protozoa. Clin Microbiol Rev 2001; 14: 150-164.
8. Sokal DC, Hieu do T, Loan ND, Hubacher D, Nanda K, Weiner DH, Vach TH: Safety of quinacrine contraceptive pellets: results from 10-year follow-up in Vietnam. Contraception 2008; 78: 66-72.
9. Dabancens A, Zipper J, Guerrero A: Quinacrine and copper, compounds with anticonceptive and antineoplastic activity. Contraception 1994; 50: 243-251.
10. Zipper J, Dabancens A, Guerrero A, Trujillo V: Quinacrine: sclerosing agent of the uterotubal junction in women, with anticarcinogenic actions in transplanted tumors in mice. Int J Gynaecol Obstet 1995; 51(suppl 1): S47-S55.
11. Zipper J, Dabancens A, Guerrero A, Trujillo V: Quinacrine revised. Hum Reprod Update 1995; 1: 324-342.
12. Hays CW: The United States Army and malaria control in World War II. Parassitologia 2000; 42: 47-52.
13. Shaw P, Agarwal R: Pleurodesis for malignant pleural effusions. Cochrane Database Syst Rev 2004;CD002916.
14. Zipper J, Trujillo V: 25 years of quinacrine sterilization experience in Chile: review of 2,592 cases. Int J Gynaecol Obstet 2003; 83(suppl 2):S23-S29.
15. Friedman J, Nottingham L, Duggal P, Pernas FG, Yan B, Yang XP, Chen Z, Van Waes C: Deficient TP53 expression, function, and cisplatin sensitivity are restored by quinacrine in head and neck cancer. Clin Cancer Res 2007; 13: 6568-6578.
16. de Souza PL, Castillo M, Myers CE: Enhancement of paclitaxel activity against hormone-refractory prostate cancer cells in vitro and in vivo by quinacrine. Br J Cancer1997; 75: 1593-1600.
17. Reyes S, Herrera LA, Ostrosky P, Sotelo J: Quinacrine enhances carmustine therapy of experimental rat glioma. Neurosurgery 2001; 49: 969-973.
18. Briceno E, Reyes S, Sotelo J: Therapy of glioblastoma multiforme improved by the antimutagenic chloroquine. Neurosurg Focus 2003; 14:e3.
19. Wang LX, Agulnik M: Promising newer molecular-targeted therapies in head and neck cancer. Drugs 2008; 68: 1609-1619.
20. Sotelo J, Guevara P, Reyes S, Arrieta O: Interstitial quinacrine for elimination of abnormal tissue; therapy of experimental glioma. Surgery 2000; 128: 439-446.
21. Deveraux QL, Roy N, Stennicke HR, Van Arsdale T, Zhou Q, Srinivasula SM, Alnemri ES, Salvesen GS, Reed JC: IAPs block apoptotic events induced by caspase-8 and cytochrome c by direct inhibition of distinct caspases. EMBO J 1998; 17: 2215-2223.
22. Hengartner MO: The biochemistry of apoptosis. Nature 2000; 407: 770-776.
23. Goyal L: Cell death inhibition: keeping caspases in check. Cell 2001; 104: 805-808.
24. Verhagen AM, Coulson EJ, Vaux DL: Inhibitor of apoptosis proteins and their relatives: IAPs and other BIRPs. Genome Biol 2001; 2: REVIEWS3009.
25. Gogvadze V, Orrenius S: Mitochondrial regulation of apoptotic cell death. Chem Biol Interact 2006; 163: 4-14.
26. Green DR, Kroemer G: Cytoplasmic functions of the tumour suppressor p53. Nature 2009; 458: 1127-1130.
27. Lalier L, Cartron PF, Juin P, Nedelkina S, Manon S, Bechinger B, Vallette FM: Bax activation and mitochondrial insertion during apoptosis. Apoptosis 2007; 12: 887-896.
28. Garrido C, Galluzzi L, Brunet M, Puig PE, Didelot C, Kroemer G: Mechanisms of cytochrome c release from mitochondria. Cell Death Differ 2006; 13: 1423-1433.
29. Gurova KV, Hill JE, Guo C, Prokvolit A, Burdelya LG, Samoylova E, Khodyakova AV, Ganapathi R, Ganapathi M, Tararova ND, Bosykh D, Lvovskiy D, Webb TR, Stark GR, and Gudkov AV: Small molecules that reactivate p53 in renal cell carcinoma reveal a NF-- Bdependent mechanism of p53 suppression in tumors. Proc Natl Acad Sci USA 2005; 102: 17448-17453.
30. Guo C, Gasparian AV, Zhuang Z, Bosykh DA, Komar AA, Gudkov AV, Gurova KV: 9-Aminoacridine-based anticancer drugs target the PI3K/AKT/mTOR, NF-kappaB and p53 pathways. Oncogene 2009; 28: 1151-1161.